Our mission
Academic Investment Center

At CALYM, our vision is to pioneer transformative advancements in the understanding and treatment of lymphoid malignancies. We aspire to be a global leader in collaborative research, pushing the boundaries of knowledge to improve patient outcomes.

Our mission is to bring together the brightest minds from academia and the private sector to conduct innovative research in lymphoid malignancies. Through strategic partnerships, proactive research development, and catalytic initiatives, we aim to accelerate innovation and its transfer, secure funding, and drive positive change in the field.

From Insight to Impact

By combining the expertise and resources of all its members, the Institut Carnot CALYM offers a unique R&D service in the diagnosis and treatment of lymphoma, from the identification of new targets to phase 3 international clinical trials and beyond.

Expertise, tools, models, platforms, databases and collections of biological resources can be rapidly mobilised to carry out your research programms.

Calym provides expertises across the R&D value chain
  • Identification of new targets
  • In vitro evaluation
  • In vivo preclinical studies
  • Clinical trials from phase 1 to phase 4
  • Validation and discovery of biomarkers
  • Valorisation and exploitation of healthcare data
Calym develops and operates technological platforms to support your projects

Connect with us !

Follow all our news on

Think Tank Innovation

The consortium thrives on the dynamic synergy between preclinical and clinical research. The Think Tank Innovation, a cross-functional gathering of esteemed professionals, fosters innovative ideas and facilitates actionable projects in lymphoma research.

The think tank initiates projects, shapes R&D initiatives, identifies advocates, and promotes unity among consortium members, playing a pivotal role in advancing lymphoma research.

The Think Tank serves as a dynamic platform for showcasing technological platforms and therapeutic innovations in onco-haematology, facilitating exploration of their potential applications.

Playing a crucial role, the Think Tank seeks expert advice to strategically position new molecules in lymphoma, foster development synergies, present innovative platforms, and identify requirements for meaningful partnerships. This sets the stage for future collaborative efforts in advancing lymphoma research and fostering innovation.

Calym’s RedTalks Webinars!

Embark on a fascinating journey into the world of lymphomas, LLC, and related diseases with our exclusive “Calym’s RedTalks Webinars” series. Launched in the fall of 2020, these webinars are your passport to cutting-edge knowledge, expert insights, and the latest advancements in the field.

Immerse yourself in a world of education as we bring renowned experts like L. Pasqualucci, M. Sadelain, W. Beguelin, A. Younes, and more, directly to your screen. Explore diverse topics, from the intricacies of epigenetics to the revolutionary developments in CAR-T therapies, and beyond.

Knowledge knows no boundaries! Our webinars are open, free, and accessible to everyone, regardless of geographical location. Whether you’re a healthcare professional, a patient, or simply curious about the forefront of medical research, Calym’s RedTalks welcomes you.

All the information you need is just a click away on our website. Stay tuned for updates on upcoming webinars, catch up on previous sessions, and join a global community passionate about advancing our understanding of lymphomas and related diseases.

Be part of the conversation, stay informed, and be inspired. Calym’s RedTalks Webinars are more than just presentations – they’re a gateway to a world where knowledge empowers progress.

Annual report

The Institut Carnot CALYM is pleased to present its latest activity report.

To access it, you can click on the button below.

une main gantée tenant un tube d'analyse


Building Strong Alliances for Breakthroughs

CALYM is a proactive organization that plays a pivotal role in advancing research in lymphoid malignancies by promoting collaboration, supporting academic research development, facilitating relationship-building, and catalyzing cross-disciplinary initiatives.
Explore our current collaborators and learn about the synergies driving our research forward.

Our Network


CALYM and Embleema’s combination of world-class capabilities brings unique R&D solutions to sponsors for enhanced patient recruitment, consent and engagement, fully-consented and auditable data interchange and generation of regulatory-grade evidence.

Embleema provides blockchain-enforced patient consent management for clinical and long-term follow-up studies and regulatory-grade evidence generation through its HIVE big data and bioinformatics platform currently in use by the U.S. Food and Drug Administration and by CDISC for defining evidence generation standards in cell and gene therapy. For more information, please visit this link.


Medical imaging data, including 2D histopathological sections and 3D PET-CT images, are crucial for the diagnosis and monitoring of patients with lymphoma. Although histopathology remains the cornerstone of lymphoma diagnosis, pathological data can be challenging to generate through automated procedures as they consist of images that require subjective interpretation by pathologists.

This hinders the reproducibility of pathological results, including lymphoma typing, and can significantly impact the management of lymphoma patients.
The collaboration between the Carnot CALYM Institute and Euranova aims to address these challenges by developing cutting-edge AI solutions to assist physicians in their therapeutic decisions.


With a commitment to fostering open innovation, the Institut Carnot Calym is proud to endorse the ATLAS project, an ambitious 4-year public/private collaboration, led by scientists Dr Sandrine Roulland, Dr Bertrand Nadel and Dr Pierre Milpied from the French National Institute Of Health And Medical Research (Inserm) through the Centre d’Immunologie de Marseille-Luminy and the Translation Medicine Team from Bristol Myers Squibb (BMS), and supported by Canceropole Provence-Alpes-Côte d’Azur.

Implementing cutting-edge techniques and state-of-the-art high-resolution and dynamic analysis of tumors within their microenvironment, the research teams are building a cell “ATLAS” to unveil the key biological parameters associated with transformation, tumor growth, relapse and resistance to treatment. This innovative and disruptive research project benefits from biological samples from the CeVi collection of live lymphoma cells set up by CALYM and the clinical expertise of LYSA members.

Empowered by this groundbreaking and exemplary partnership, researchers are transcending sector and disciplinary confines, working collaboratively to produce results with tangible diagnostic and theranostic implications that will, in the long run, directly benefit patients.

About us

CALYM is an non-profit organization (Association Loi 1901) that accelerates innovation and its transfer to industry in the field of malignant lymphoid diseases. Working in partnership with academia and industry, it has a professional team dedicated to partnership research and academic investment. As manager of the Calym Carnot Institute, CALYM coordinates the expertise and skills of its members to support innovative and ambitious research projects that have a real impact on patients.